Unknown

Dataset Information

0

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.


ABSTRACT: International trials have shown that CD4+ T-cell-guided structured treatment interruptions (STI) of antiretroviral therapy (ART) lead to worse outcomes than continuous treatment. We simulated continuous ART and STI strategies with higher CD4+ T-cell interruption/reintroduction thresholds than those assessed in actual trials.Using a model of HIV, we simulated cohorts of African adults with different baseline CD4+ T-cell counts (< or = 200; 201-350; and 351-500 cells/microl). We varied ART initiation criteria (immediate; CD4+ T-cell count < 350 cells/microl or > or = 350 cells/microl with severe HIV-related disease; and CD4+ T-cell count <200 cells/microl or > or = 200 cells/microl with severe HIV-related disease), and ART interruption/reintroduction thresholds (350/250; 500/350; and 700/500 cells/microl). First-line therapy was non-nucleoside reverse transcriptase inhibitor (NNRTI)-based and second-line therapy was protease inhibitor (PI)-based.STI generally reduced life expectancy compared with continuous ART. Life expectancy increased with earlier ART initiation and higher interruption/reintroduction thresholds. STI reduced life expectancy by 48-69 and 11-30 months compared with continuous ART when interruption/reintroduction thresholds were 350/250 and 500/350 cells/microl, depending on ART initiation criteria. When patients interrupted/reintroduced ART at 700/500 cells/microl, life expectancies ranged from 2 months lower to 1 month higher than continuous ART. STI-related life expectancy increased with decreased risk of virological resistance after ART interruptions.STI with NNRTI-based regimens was almost always less effective than continuous treatment, regardless of interruption/reintroduction thresholds. The risks associated with STI decrease only if patients start ART earlier, interrupt/reintroduce treatment at very high CD4+ T-cell thresholds (700/500 cells/microl) and use first-line medications with higher resistance barriers, such as PIs.

SUBMITTER: Yazdanpanah Y 

PROVIDER: S-EPMC3220615 | biostudies-other | 2010

REPOSITORIES: biostudies-other

altmetric image

Publications

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.

Yazdanpanah Yazdan Y   Wolf Lindsey L LL   Anglaret Xavier X   Gabillard Delphine D   Walensky Rochelle P RP   Moh Raoul R   Danel Christine C   Sloan Caroline E CE   Losina Elena E   Freedberg Kenneth A KA  

Antiviral therapy 20100101 3


<h4>Background</h4>International trials have shown that CD4+ T-cell-guided structured treatment interruptions (STI) of antiretroviral therapy (ART) lead to worse outcomes than continuous treatment. We simulated continuous ART and STI strategies with higher CD4+ T-cell interruption/reintroduction thresholds than those assessed in actual trials.<h4>Methods</h4>Using a model of HIV, we simulated cohorts of African adults with different baseline CD4+ T-cell counts (< or = 200; 201-350; and 351-500 c  ...[more]

Similar Datasets

| S-EPMC6005325 | biostudies-literature
| S-EPMC10002475 | biostudies-literature
| S-EPMC6688772 | biostudies-literature
| S-EPMC3548111 | biostudies-other
| S-EPMC3293185 | biostudies-literature
| S-EPMC4725846 | biostudies-literature
| S-EPMC7205565 | biostudies-literature
| S-EPMC7987773 | biostudies-literature
| S-EPMC3657555 | biostudies-literature
| S-EPMC3125169 | biostudies-literature